Prognostic factors in the relapse of Graves' disease following treatment with antithyroid drugs

Iranian Journal of Medical Sciences

Volumn 28, Issue 3, 2003, Pages 106-110

  Soveid, M ^a   Shaabani, A ^a   Ghaedi, Gh H ^a   Jafari, S M ^a   Omrani, Gh ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Graves' disease; Iodized salt; Iran; Relapse

Indexed keywords

ANTITHYROID AGENT; LIOTHYRONINE; PROPYLTHIOURACIL; SODIUM CHLORIDE; THIAMAZOLE; THYROXINE;

ADULT; AGE; ARTICLE; DRUG DOSE REGIMEN; FEMALE; FOOD INTAKE; GENDER; GRAVES DISEASE; HUMAN; IODINATION; IRAN; LIOTHYRONINE BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RELAPSE; REMISSION; THYROID GLAND; THYROXINE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 2942746192     PISSN: 02530716     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Leech NJ, Dayan CM: Controversies in the management of Graves' disease. Clin Endocrinol 1998; 49(3): 273-80.
2. Wartofsky L, Glinoer D, Solomon B, Lagasser R: Difference and similarities in the treatment of diffuse goiter in Eruope and the United States. Exp Clin Endocrinol 1991; 97(2-3): 243-51.
3. Allahabadia A, Daykin J, Holder RL, et al: Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinal Metab 2000; 85(3): 1038-42.
4. Holm LE, Alinder I: Relapse after thionamide therapy for Graves' disease. Acta Med scand 1982; 211(6): 489-92.
5. Azizi F, Kimiagar M, Nafarabadi M, et al: Current status of iodine deficiency in the Islamic republic of Iran. EMR Health Ser J 1990; 8: 23-7.
6. Assessment of monitoring of iodine deficiency disorders in countries of the Eastern Mediterranean Region. WHO-EMRO. Report of a symposium workshop. 9-11 Sept 1999; Tehran, I. R. Iran, 2000.
7. Thilly CH, Delange F, Stanbury JB: Epidemiological surveys in endemic goiter and cretinism. In: Stanbury JB, Hetzel BS, et al, eds: Endemic goiter and endemic cretinism: Iodine nutrition in health and disease. New York: John Wiley, 1980: 157-83.
8. Werner SC: Modification of the classification of the eye changes in Graves' disease: recommendation of the ad hoc committee of the American Thyroid Association. J Clin Endocrinal Metab 1977; 44(1): 203-4.
9. th ed. Philadelphia: W B Saunders, 1998: 389-515.
10. Chiou SC, Houng HS, Li KL, et al: Outcome of Graves' thyrotoxicosis after antithyroid drug treatment. Changkeng Yi Xue Za Zhi 1995; 18(4): 305-14.
11. Torring O, Tallstedt L, Wallin G, et al: Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine. J Clin Endocrinal Metab 1996; 81(8): 2986-93.
12. Winsa B, Dahlberg A, Jansson R, et al: Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinol Copenh 1990; 122(6): 722-8.
13. Vitti P, Rago T, Chiovato L, et al: Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7(3): 369-75.
14. Corvilain B, Van Sande J, Dumont JE, et al: Autonomy in endemic goiter. Thyroid 1998; 8(1): 107-15.
15. Allannic H, Fauchet R, Orgiazzi J, et al: Antithyroid drugs and Graves' disease a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70(3): 675-9.
16. Tajiri J, Noguchi S, Morita M, et al: Serum free triiodothyronine to free thyroxine ratio enables early prediction of the outcome of antithyroid drug therapy in patients with Graves' hyperthyroidism. Endocrinol Jpn 1991; 38(6): 683-7.
17. Gauna AT, Guillen CE, Sartorio GC, Soto RJ: Graves' disease: evolution and prognosis after eight months of treatment with methimazole. Medicina 1992; 52(3): 207-12.
18. Ikenoue H, Okamura K, Sato K, et al: Prediction of relapse in drug treated Graves' disease using thyroid stimulating indices. Acta endocrinol (copenh) 1991; 125(6): 643-50.
19. Schleusener H, Schwander J, Fischer c, et al: Prospective multicenter study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (copenh) 1989; 120(6): 689-701.
20. Laurberg P, Buchholtz Hansen PE, Iversen E, et al: Goiter size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Copenh) 1986; 111(1): 29-43.
21. Kimball LE, Kulinskaya E, Brown B, et al: Does smoking increase relapse rates in Graves' disease? J Endocrinol invest 2002; 25 (2):152-7.
22. Bolanos F, Gonzalez-Ortiz M, Duron H, et al: Remission of Graves' hyperthyroidism treated with methumazole. Rev Invest Clin 2002; 54(4): 307-10.
23. Nedrebo BG, Holm PI, Uhlving S, et al: Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinal 2002; 147(5): 583-9.
24. Schumm-Draeger PM: Basedow disease hyperthyroidism: Is there a therapeutic standard? Zentralbe Chir 1997; 122(4): 224-6.
25. Weetman AP, Pickerill AP, Watson P, et al: Treatment of Graves' disease with block replace regimen of antithyroid drugs: the effect of treatment duration on relapse. Q J Med 1994; 87(6): 337-41.
26. Roti E, Uberti ED: Iodine excess and hyperthyroidism. Thyroid 2001; 11(5): 493-500.
27. rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001 :360-6.
28. Lind P, Kumnig G, Heinlsch M, et al: Iodine supplementation in Austria: methods and results. Thyroid 2002; 12(10): 903-7.
29. Weetman AP, Mc Gregor AM, Campbell H, et al: Iodide enhances IgG synthesis by human peripheral blood lymphocytes in vitro. Acta Endocrinol 1983; 103(2): 210-5.
30. Sundick RS, Bagchi N, Brown TR: The role of iodine in thyroid autoimmunity: from chickens to humans: a review. Autoimmunity 1992; 13(1):61-8.
31. Sztankay A, Trieb K, Lucciarini P, et al: Interferon gamma and iodine increase the inducibility of the 72 KD heat shock protein in cultured human thyroid epithelial cells. J Autoimmun 1994; 7(2): 219-30.
32. Ruwhof C, Drexhage HA: Iodine and thyroid autoimmune disease in animal models. Thyroid 2001; 11(5): 427-36.
33. Solomon BL, Evaul JE, Burman KD: Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann Intem Med 1987; 107(4): 510-12.
34. Lumholtz IB, Poulsen DL, Siersbaek-Nielsen K, et al: Outcome of long-term antithyroid treatment of Graves' disease in relation to iodine intake. Acta Endocrinol (Copenh) 1977; 84(3): 538-41.
35. Thjodleifsson B: A study of Graves' disease in Iceland. Acta Med Scand 1975; 198(4): 309-14.